StockNews.AI
JAGX
StockNews.AI
141 days

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

1. Jaguar's revenue grew 20% to $11.7 million in 2024. 2. POC trial results for crofelemer expected in Q2 2025.

3m saved
Insight
Article

FAQ

Why Bullish?

The significant revenue growth and upcoming trial results signal potential investor confidence. Historical patterns show that similar positive financial news can lead to favorable stock price movements for biotech firms.

How important is it?

Revenue growth and upcoming trial outcomes are critical for JAGX's market perception and valuation. Investors are likely to respond favorably to both financial and clinical progress.

Why Short Term?

Anticipation of POC results in Q2 2025 may drive immediate investor interest, affecting prices. Typically, biotech stocks react quickly to news related to clinical trials.

Related Companies

JAGX
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESS Newswire / March 31, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024.

Related News